<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p61" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_61{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_61{left:341px;bottom:30px;}
#t3_61{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_61{left:377px;bottom:30px;}
#t5_61{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_61{left:540px;bottom:30px;}
#t7_61{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_61{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_61{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_61{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_61{left:285px;bottom:827px;letter-spacing:-0.39px;word-spacing:0.12px;}
#tc_61{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_61{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_61{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_61{left:1109px;bottom:28px;letter-spacing:0.29px;}
#tg_61{left:36px;bottom:282px;}
#th_61{left:46px;bottom:276px;letter-spacing:0.12px;}
#ti_61{left:45px;bottom:260px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tj_61{left:408px;bottom:260px;}
#tk_61{left:36px;bottom:249px;}
#tl_61{left:42px;bottom:243px;letter-spacing:0.12px;}
#tm_61{left:45px;bottom:226px;letter-spacing:0.13px;}
#tn_61{left:45px;bottom:209px;letter-spacing:0.11px;}
#to_61{left:45px;bottom:192px;letter-spacing:0.12px;}
#tp_61{left:384px;bottom:192px;letter-spacing:0.05px;word-spacing:0.11px;}
#tq_61{left:470px;bottom:192px;}
#tr_61{left:36px;bottom:182px;}
#ts_61{left:46px;bottom:176px;letter-spacing:0.12px;}
#tt_61{left:45px;bottom:159px;letter-spacing:0.1px;word-spacing:0.02px;}
#tu_61{left:36px;bottom:148px;}
#tv_61{left:42px;bottom:142px;letter-spacing:0.13px;}
#tw_61{left:257px;bottom:142px;}
#tx_61{left:36px;bottom:131px;}
#ty_61{left:50px;bottom:125px;letter-spacing:0.12px;}
#tz_61{left:81px;bottom:125px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t10_61{left:366px;bottom:125px;letter-spacing:0.12px;}
#t11_61{left:45px;bottom:108px;letter-spacing:0.12px;}
#t12_61{left:129px;bottom:108px;letter-spacing:0.15px;}
#t13_61{left:178px;bottom:108px;}
#t14_61{left:36px;bottom:778px;letter-spacing:0.47px;}
#t15_61{left:36px;bottom:760px;letter-spacing:0.23px;}
#t16_61{left:359px;bottom:778px;letter-spacing:0.29px;word-spacing:-0.13px;}
#t17_61{left:552px;bottom:786px;}
#t18_61{left:690px;bottom:778px;letter-spacing:0.28px;word-spacing:-0.12px;}
#t19_61{left:897px;bottom:786px;}
#t1a_61{left:1065px;bottom:778px;letter-spacing:0.34px;}
#t1b_61{left:1065px;bottom:604px;letter-spacing:-0.1px;}
#t1c_61{left:1065px;bottom:585px;letter-spacing:-0.09px;}
#t1d_61{left:1065px;bottom:567px;letter-spacing:-0.08px;}
#t1e_61{left:1069px;bottom:508px;letter-spacing:-0.09px;}
#t1f_61{left:1069px;bottom:489px;letter-spacing:-0.06px;}
#t1g_61{left:1069px;bottom:471px;letter-spacing:-0.08px;}
#t1h_61{left:1069px;bottom:453px;letter-spacing:-0.09px;}
#t1i_61{left:1069px;bottom:434px;letter-spacing:-0.25px;}
#t1j_61{left:36px;bottom:610px;letter-spacing:-0.09px;}
#t1k_61{left:36px;bottom:591px;letter-spacing:-0.1px;}
#t1l_61{left:204px;bottom:599px;}
#t1m_61{left:217px;bottom:591px;letter-spacing:-0.07px;}
#t1n_61{left:36px;bottom:573px;letter-spacing:-0.1px;}
#t1o_61{left:36px;bottom:555px;letter-spacing:-0.09px;}
#t1p_61{left:36px;bottom:476px;letter-spacing:-0.09px;}
#t1q_61{left:36px;bottom:458px;letter-spacing:-0.1px;}
#t1r_61{left:111px;bottom:465px;}
#t1s_61{left:124px;bottom:458px;letter-spacing:-0.09px;}
#t1t_61{left:36px;bottom:439px;letter-spacing:-0.09px;}
#t1u_61{left:36px;bottom:421px;letter-spacing:-0.1px;}
#t1v_61{left:355px;bottom:628px;letter-spacing:-0.1px;}
#t1w_61{left:419px;bottom:636px;letter-spacing:-0.09px;}
#t1x_61{left:439px;bottom:628px;letter-spacing:-0.08px;}
#t1y_61{left:355px;bottom:610px;letter-spacing:-0.1px;}
#t1z_61{left:355px;bottom:591px;letter-spacing:-0.13px;}
#t20_61{left:378px;bottom:599px;letter-spacing:-0.13px;}
#t21_61{left:355px;bottom:573px;letter-spacing:-0.1px;}
#t22_61{left:355px;bottom:555px;letter-spacing:-0.1px;}
#t23_61{left:615px;bottom:562px;letter-spacing:-0.15px;}
#t24_61{left:690px;bottom:658px;letter-spacing:-0.13px;}
#t25_61{left:712px;bottom:666px;letter-spacing:-0.12px;}
#t26_61{left:690px;bottom:640px;letter-spacing:-0.06px;}
#t27_61{left:690px;bottom:621px;letter-spacing:-0.1px;}
#t28_61{left:932px;bottom:629px;letter-spacing:-0.15px;}
#t29_61{left:690px;bottom:603px;letter-spacing:-0.09px;}
#t2a_61{left:690px;bottom:585px;letter-spacing:-0.09px;}
#t2b_61{left:845px;bottom:592px;}
#t2c_61{left:359px;bottom:482px;letter-spacing:-0.13px;}
#t2d_61{left:381px;bottom:489px;}
#t2e_61{left:359px;bottom:439px;letter-spacing:-0.1px;}
#t2f_61{left:359px;bottom:393px;letter-spacing:-0.27px;}
#t2g_61{left:426px;bottom:400px;letter-spacing:-0.09px;}
#t2h_61{left:446px;bottom:393px;letter-spacing:-0.08px;}
#t2i_61{left:692px;bottom:439px;letter-spacing:-0.13px;}
#t2j_61{left:714px;bottom:446px;}
#t2k_61{left:692px;bottom:420px;letter-spacing:-0.06px;}
#t2l_61{left:692px;bottom:402px;letter-spacing:-0.11px;}
#t2m_61{left:759px;bottom:410px;}
#t2n_61{left:772px;bottom:402px;letter-spacing:-0.09px;word-spacing:-0.09px;}
#t2o_61{left:692px;bottom:384px;letter-spacing:-0.1px;}
#t2p_61{left:692px;bottom:365px;letter-spacing:-0.1px;}
#t2q_61{left:692px;bottom:347px;letter-spacing:-0.13px;}
#t2r_61{left:714px;bottom:355px;letter-spacing:-0.11px;}
#t2s_61{left:742px;bottom:347px;letter-spacing:-0.09px;}
#t2t_61{left:692px;bottom:329px;letter-spacing:-0.09px;}
#t2u_61{left:847px;bottom:336px;}
#t2v_61{left:594px;bottom:266px;}
#t2w_61{left:604px;bottom:260px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2x_61{left:1114px;bottom:260px;}
#t2y_61{left:594px;bottom:249px;}
#t2z_61{left:604px;bottom:243px;letter-spacing:-0.04px;}
#t30_61{left:603px;bottom:226px;letter-spacing:-0.04px;}
#t31_61{left:603px;bottom:209px;letter-spacing:-0.02px;}
#t32_61{left:594px;bottom:198px;}
#t33_61{left:604px;bottom:192px;letter-spacing:-0.03px;}
#t34_61{left:603px;bottom:176px;letter-spacing:-0.04px;}
#t35_61{left:603px;bottom:159px;letter-spacing:-0.04px;}
#t36_61{left:603px;bottom:142px;letter-spacing:-0.04px;}
#t37_61{left:603px;bottom:125px;}
#t38_61{left:608px;bottom:125px;letter-spacing:-0.02px;}
#t39_61{left:680px;bottom:125px;letter-spacing:-0.07px;}
#t3a_61{left:594px;bottom:114px;}
#t3b_61{left:601px;bottom:108px;letter-spacing:0.11px;word-spacing:0.01px;}
#t3c_61{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_61{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_61{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_61{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_61{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_61{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_61{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_61{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_61{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_61{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_61{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_61{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_61{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_61{font-size:14px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_61{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts61" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg61Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg61" style="-webkit-user-select: none;"><object width="1210" height="935" data="61/61.svg" type="image/svg+xml" id="pdf61" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_61" class="t s0_61">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_61" class="t s1_61">® </span>
<span id="t3_61" class="t s0_61">(NCCN </span>
<span id="t4_61" class="t s1_61">® </span>
<span id="t5_61" class="t s0_61">), All rights reserved. NCCN Guidelines </span>
<span id="t6_61" class="t s1_61">® </span>
<span id="t7_61" class="t s0_61">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_61" class="t s2_61">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_61" class="t s2_61">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_61" class="t s3_61">NCCN Guidelines Version 4.2024 </span>
<span id="tb_61" class="t s3_61">Ethmoid Sinus Tumors </span>
<span id="tc_61" class="t s4_61">NCCN Guidelines Index </span>
<span id="td_61" class="t s4_61">Table of Contents </span>
<span id="te_61" class="t s4_61">Discussion </span>
<span id="tf_61" class="t s5_61">ETHM-3 </span>
<span id="tg_61" class="t s6_61">h </span>
<span id="th_61" class="t s7_61">See the salivary gland algorithm for management after resection. See </span>
<span id="ti_61" class="t s8_61">NCCN Guidelines for Salivary Gland Tumors (SALI-1)</span><span id="tj_61" class="t s7_61">. </span>
<span id="tk_61" class="t s6_61">j </span>
<span id="tl_61" class="t s7_61">For SNUC with neuroendocrine features, small cell, high-grade olfactory </span>
<span id="tm_61" class="t s7_61">esthesioneuroblastoma, or SNEC histologies, systemic therapy should be a </span>
<span id="tn_61" class="t s7_61">part of the overall treatment. Consider a clinical trial and referral to a major </span>
<span id="to_61" class="t s9_61">medical center that specializes in these diseases. </span><span id="tp_61" class="t s8_61">See SYST-A</span><span id="tq_61" class="t s7_61">. </span>
<span id="tr_61" class="t s6_61">k </span>
<span id="ts_61" class="t s9_61">N+ neck disease is uncommon in ethmoid cancers, but, if present, requires </span>
<span id="tt_61" class="t s7_61">neck dissection and appropriate risk-based adjuvant therapy. </span>
<span id="tu_61" class="t s6_61">l </span>
<span id="tv_61" class="t s8_61">Principles of Surgery (SURG-A)</span><span id="tw_61" class="t s7_61">. </span>
<span id="tx_61" class="t s6_61">m </span>
<span id="ty_61" class="t s7_61">See </span><span id="tz_61" class="t s8_61">Principles of Radiation Therapy (ETHM-A)</span><span id="t10_61" class="t s7_61">. For minor salivary gland </span>
<span id="t11_61" class="t s7_61">tumors, see </span><span id="t12_61" class="t s8_61">SALI-A</span><span id="t13_61" class="t s7_61">. </span>
<span id="t14_61" class="t s5_61">CLINICAL </span>
<span id="t15_61" class="t s5_61">PRESENTATION </span>
<span id="t16_61" class="t s5_61">PRIMARY TREATMENT </span>
<span id="t17_61" class="t sa_61">j </span>
<span id="t18_61" class="t s5_61">ADJUVANT TREATMENT </span>
<span id="t19_61" class="t sa_61">j </span>
<span id="t1a_61" class="t s5_61">FOLLOW-UP </span>
<span id="t1b_61" class="t s5_61">Follow-up </span>
<span id="t1c_61" class="t sb_61">(FOLL-A, 1 </span>
<span id="t1d_61" class="t sb_61">of 2) </span>
<span id="t1e_61" class="t s5_61">Recurrent </span>
<span id="t1f_61" class="t s5_61">or </span>
<span id="t1g_61" class="t s5_61">persistent </span>
<span id="t1h_61" class="t s5_61">disease </span>
<span id="t1i_61" class="t sb_61">(ADV-3) </span>
<span id="t1j_61" class="t s5_61">Diagnosed after </span>
<span id="t1k_61" class="t s5_61">incomplete resection </span>
<span id="t1l_61" class="t sa_61">h </span>
<span id="t1m_61" class="t s5_61">(eg, </span>
<span id="t1n_61" class="t s5_61">polypectomy) and gross </span>
<span id="t1o_61" class="t s5_61">residual disease </span>
<span id="t1p_61" class="t s5_61">Diagnosed after incomplete </span>
<span id="t1q_61" class="t s5_61">resection </span>
<span id="t1r_61" class="t sa_61">h </span>
<span id="t1s_61" class="t s5_61">(eg, polypectomy) and </span>
<span id="t1t_61" class="t s5_61">no residual disease on physical </span>
<span id="t1u_61" class="t s5_61">exam, imaging, and/or endoscopy </span>
<span id="t1v_61" class="t s5_61">Surgery </span>
<span id="t1w_61" class="t sa_61">k,l </span>
<span id="t1x_61" class="t s5_61">(preferred), if feasible </span>
<span id="t1y_61" class="t s5_61">or </span>
<span id="t1z_61" class="t s5_61">RT </span>
<span id="t20_61" class="t sa_61">m,r </span>
<span id="t21_61" class="t s5_61">or </span>
<span id="t22_61" class="t s5_61">Concurrent systemic therapy/RT </span>
<span id="t23_61" class="t sa_61">m,n </span>
<span id="t24_61" class="t s5_61">RT </span>
<span id="t25_61" class="t sa_61">j,m </span>
<span id="t26_61" class="t s5_61">or </span>
<span id="t27_61" class="t s5_61">Consider systemic therapy/RT </span>
<span id="t28_61" class="t sa_61">m,n </span>
<span id="t29_61" class="t s5_61">(category 2B) if adverse </span>
<span id="t2a_61" class="t s5_61">pathologic features </span>
<span id="t2b_61" class="t sc_61">q </span>
<span id="t2c_61" class="t s5_61">RT </span>
<span id="t2d_61" class="t sa_61">m </span>
<span id="t2e_61" class="t s5_61">or </span>
<span id="t2f_61" class="t s5_61">Surgery, </span>
<span id="t2g_61" class="t sa_61">k,l </span>
<span id="t2h_61" class="t s5_61">if feasible </span>
<span id="t2i_61" class="t s5_61">RT </span>
<span id="t2j_61" class="t sa_61">m </span>
<span id="t2k_61" class="t s5_61">or </span>
<span id="t2l_61" class="t s5_61">Observe </span>
<span id="t2m_61" class="t sa_61">p </span>
<span id="t2n_61" class="t s5_61">for T1 only (category 2B) </span>
<span id="t2o_61" class="t s5_61">or </span>
<span id="t2p_61" class="t s5_61">Consider systemic therapy/ </span>
<span id="t2q_61" class="t s5_61">RT </span>
<span id="t2r_61" class="t sa_61">m,n </span>
<span id="t2s_61" class="t s5_61">(category 2B) if adverse </span>
<span id="t2t_61" class="t s5_61">pathologic features </span>
<span id="t2u_61" class="t sc_61">q </span>
<span id="t2v_61" class="t s6_61">n </span>
<span id="t2w_61" class="t s8_61">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2x_61" class="t s7_61">. </span>
<span id="t2y_61" class="t s6_61">p </span>
<span id="t2z_61" class="t s7_61">Pathologic features: negative margins, favorable histology (including low grade), not </span>
<span id="t30_61" class="t s7_61">located along the cribriform plate or medial wall of the orbit, no perineural invasion, </span>
<span id="t31_61" class="t s7_61">and lymphovascular space invasion. </span>
<span id="t32_61" class="t s6_61">q </span>
<span id="t33_61" class="t s7_61">Adverse pathologic features: positive margins, close margins (tumors adjacent to the </span>
<span id="t34_61" class="t s7_61">cribriform plate and/or medial wall of the orbit), unfavorable histology (ie, high grade, </span>
<span id="t35_61" class="t s7_61">adenoid cystic), intracranial and/or intraorbital extension, cribriform plate location, </span>
<span id="t36_61" class="t s7_61">medial wall of orbit location, perineural invasion, and lymphovascular space invasion </span>
<span id="t37_61" class="t s7_61">(</span><span id="t38_61" class="t s8_61">Discussion</span><span id="t39_61" class="t s7_61">). </span>
<span id="t3a_61" class="t s6_61">r </span>
<span id="t3b_61" class="t s7_61">Primary RT is an option for minimal residual squamous cell carcinoma. </span>
<span id="t3c_61" class="t sd_61">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
